Skip Navigation



European Heart Journal Advance Access published online on March 16, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn091
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/8/957    most recent
ehn091v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Holmes, D. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holmes, D. R., Jr
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Resistance to what, does it matter? How do we study it?

David R. Holmes, Jr*

Department of Cardiology, Mayo Clinic, 200 First St S.W., Rochester, MN 55905, USA

* Corresponding author. Tel: +1 507 255 2504, Fax: +1 507 255 2550, Email: dholmes@mayo.edu

This editorial refers to ‘Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation’ by M.J. Price et al., doi:10.1093/eurheartj/ehn046

The first 10% of the full text of this article appears below.

The importance of platelets and thrombosis in the pathophysiology of acute ischaemic coronary syndromes has been well appreciated. This information has formed the backbone of the guidelines on both sides of the Atlantic that patients with acute as well as chronic coronary artery disease be treated with aspirin as a long-term strategy of care. While the specific dosage schedule may vary, aspirin treatment remains a Class I indication.1 Increasingly, adherence to this as well as . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
Matthew J. Price, Sarah Endemann, Raghava R. Gollapudi, Rafael Valencia, Curtiss T. Stinis, Justin P. Levisay, Alissa Ernst, Neil S. Sawhney, Richard A. Schatz, and Paul S. Teirstein
EHJ 2008 29: 992-1000. [Abstract] [Full Text]